<DOC>
	<DOCNO>NCT00749112</DOCNO>
	<brief_summary>The purpose study determine whether combination low dose alemtuzumab rituximab effective treatment patient autoimmune cytopenia fail steroid , relapse steroid withdrawal require continuous steroid treatment .</brief_summary>
	<brief_title>Alemtuzumab Rituximab Treatment Refractory Autoimmune Cytopenias</brief_title>
	<detailed_description>Autoimmune cytopenias common entity good response steroid therapy first line , considerable percentage patient relapse , become refractory dependant steroid maintain acceptable level hemoglobin platelet , treatment becomes difficult increase secondary effect . The current study evaluate safety efficacy combination low dos alemtuzumab ( anti CD52 ) Rituximab ( anti CD 20 ) second line treatment option subset patient improve cytopenia without increase adverse effect .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age : &gt; = 16 year Weight : 40 Kg Autoimmune Hemolytic anemia clinical biochemical evidence hemolysis refractory treatment , relapse steroid dependant Idiopathic thrombocytopenic purpura platelet count &lt; 50,000 , refractory treatment , relapse steroid dependant Current viral bacterial infection . Positive serology HIV , HCV , HBV .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Anemia</keyword>
	<keyword>Hemolytic</keyword>
	<keyword>Autoimmune</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Rituximab</keyword>
</DOC>